Travel grant 2020, Zurich 6 Feb
| Reference number | |
| Coordinator | SCANDINAVIAN BIOPHARMA HOLDING AB |
| Funding from Vinnova | SEK 8 715 |
| Project duration | January 2020 - February 2020 |
| Status | Completed |
Important results from the project
** Denna text är maskinöversatt ** The goal was to meet potential investors for our planned clinical Fas III study of ETVAX in travelers.
Expected long term effects
** Denna text är maskinöversatt ** According to the plan, I met a number of potential investors. We have already booked meetings in 2020 for further discussions with three of them.
Approach and implementation
Attended the conference and pre-booked meetings with potential investors.